Outpatient injection or surgery for your hip cartilage?

Two pathways now exist for focal hip cartilage damage in active adults: an ultrasound-guided outpatient injection and a single-stage arthroscopic operation. Choosing between them is not simply a matter of preferring the less invasive option — the two procedures work through different mechanisms, take place in entirely different settings, and suit different clinical situations.

The ChondroFiller injection delivers an injectable collagen scaffold directly into the hip joint in a clinic room, under local anaesthesia, without an incision or an operating theatre. AMIC (Autologous Matrix-Induced Chondrogenesis) is a surgical procedure performed under general or spinal anaesthesia: the defect bed is prepared arthroscopically, bone marrow is stimulated, and a collagen membrane is fixed over the repair site.

Both approaches are intended for focal, contained cartilage lesions in patients typically under 55, and neither is appropriate where advanced osteoarthritis is already present. The decision between them turns on lesion grade, defect size, and a patient's readiness for surgery — not on one option being right for everyone.

The sections below set out what each procedure does, who is most likely to benefit, what the clinical evidence shows, and what recovery involves.

How ChondroFiller injection works in the hip joint

ChondroFiller is a CE-marked Class III medical device: a cell-free Type I collagen hydrogel produced by Meidrix Biomedicals in Germany. In the current clinical pathway at UK clinics, it is placed into the hip joint under ultrasound or fluoroscopic guidance, in a clinic room, without general anaesthesia or theatre admission.

Once injected into the fluid joint environment, the gel self-sets in approximately three to five minutes, moulding to the defect geometry on the femoral head or acetabulum. No bone drilling or fibrin glue is required. The scaffold then acts as an additive, top-down cushion: rather than surgically excavating the damaged surface, it sits over remaining articular cartilage and provides a structural matrix into which the patient's own progenitor cells can migrate — a process called matrix-induced chondrogenesis.

This approach is indicated for focal or diffuse Grade III–IV chondral wear, with defects typically up to 3 cm² and potentially extending to 6 cm². The underlying rationale is partly anatomical: hip articular cartilage is avascular and has very limited capacity for self-repair. An injectable scaffold provides the structural framework the joint cannot produce unaided.

Published hip cohort data support positive outcomes at three to five year follow-up; a 2021 prospective study by Mazek (PMC8460160) used arthroscopic delivery rather than the injection-based placement that defines the current outpatient pathway — meaning no surgical admission is required under today's clinical approach. Specific outcome figures from this study are examined in the evidence section below.

What AMIC surgery involves

Performed in an operating theatre under general or spinal anaesthesia, AMIC is an arthroscopic operation requiring a surgical team, a dry joint environment, and sterile theatre conditions — a procedural commitment that stands in clear contrast to the outpatient injection pathway.

The procedure follows three sequential steps. The surgeon first debrides the cartilage defect arthroscopically, removing damaged tissue back to a stable border and preparing the subchondral bone bed. Microfracture then follows: small perforations through the bone plate release bone marrow progenitor cells into the defect. On its own, microfracture produces fibrocartilage that tends to deteriorate within two to three years and risks damaging the subchondral plate — AMIC directly addresses this limitation by adding a bilayer Type I/III collagen membrane (Chondro-Gide, Geistlich), secured with fibrin glue or sutures to stabilise the marrow clot and guide the progenitor cells towards more organised repair tissue.

The mechanism is structural and bottom-up: rebuilding the defect cavity from bone level upward rather than cushioning from above.

Evidence positions this approach for younger active patients with substantial focal lesions. A 2018 systematic review and meta-analysis of 1,484 patients across 19 studies found AMIC achieved the highest pooled success rate of all hip cartilage preservation techniques at 99.7%, compared with 89.6% for microfracture alone. Registry data from 57 patients (mean defect 3.4 cm², mean age 37.3 years) confirmed significant VAS pain reductions (p<0.001) maintained at two years. The technique has over a decade of published clinical use, though randomised trial data remain limited; a pilot multi-centre RCT (NCT05402072) comparing AMIC with microfracture in 40 patients aged 18–55 is currently under way and will eventually provide the first randomised evidence for this setting.

Which patients are suited to each approach

Matching patient to procedure turns on four factors: lesion grade, defect size, age and activity level, and the degree of background joint wear.

Lesion grade and defect size

Both procedures target moderate to severe chondral damage — Grade III (thinning beyond half the cartilage depth) or Grade IV (full-thickness loss to subchondral bone). For the ChondroFiller injection, focal defects up to approximately 3 cm² are supported by evidence, with some data extending this to 6 cm²; the fluid form moulds to irregular or complex defect geometries without requiring a surgically prepared bed. AMIC evidence clusters around a mean defect of 3.4 cm² in registry data and 2.5 cm² in the O'Connor meta-analysis of 1,484 patients; defect containment is a technical prerequisite for membrane fixation to succeed.

Age and surgical fitness

AMIC evidence is strongest in younger, active patients — mean age approximately 37–38 years across registry and meta-analysis datasets. The ChondroFiller injection pathway does not carry a published hard age ceiling and may suit patients who cannot tolerate general or spinal anaesthesia, or whose lesion profile does not reach surgical thresholds.

Where neither applies

The Mazek cohort found poor outcomes in patients with pre-existing Tönnis grade 2–3 osteoarthritis — a finding that reinforces what AMIC data show equally: established diffuse joint wear leaves the cartilage environment too degraded for scaffold integration or membrane-guided repair, regardless of which approach is under consideration.

Lifestyle and preference

The outpatient injection path carries a shorter immediate interruption to daily life; AMIC demands a greater short-term surgical commitment but offers a structural rebuild for suitable candidates. Where both are technically eligible, patient preference and rehabilitation capacity are legitimate parts of the clinical conversation.

MRI imaging and specialist assessment are needed to confirm lesion grade, defect geometry, and background OA status before any treatment decision is reached.

What the clinical evidence shows

The strongest direct evidence for the ChondroFiller injection pathway in the hip comes from Mazek 2021 (PMC8460160): a prospective cohort of 26 patients with FAI and acetabular lesions larger than 2 cm², of whom 17 of 21 evaluable patients achieved good or excellent results on both MRI and functional scoring at three to five years. Across the broader published literature, 70–85% of patients treated with ChondroFiller across hip and other joint applications achieve meaningful symptom relief at three to five years — a consistent headline, though one that rests more on clinical series than multicentre randomised trials.

AMIC's evidence base, as detailed in the previous section, is substantially larger in scale. The headline figure — 99.7% pooled success in the O'Connor meta-analysis — is drawn from 1,484 patients across 19 hip-specific studies, with registry data confirming gains in pain and function maintained through two years.

No head-to-head RCT comparing the ChondroFiller injection with AMIC in the hip has been conducted. That is not a clinical judgement on either procedure; it is a structural fact that limits what can be said with certainty. The practical implication is this: when a patient's lesion profile makes both options technically eligible, the asymmetry in evidence volume — a single cohort of 26 against a pooled analysis of more than 1,400 — is a legitimate clinical consideration. Where surgery is not appropriate or not wanted, the ChondroFiller injection data still support a reasonable likelihood of meaningful benefit in well-selected patients. The difference in evidence depth reflects different procedural histories, not a simple quality hierarchy.

An ongoing pilot RCT (NCT05402072) is building comparative evidence for AMIC against microfracture, which will help clarify where AMIC sits within the broader cartilage preservation landscape.

Recovery, rehabilitation, and how to take the next step

The two procedures diverge most sharply in the days immediately after treatment.

After a ChondroFiller injection — administered in an outpatient clinic without theatre admission or general anaesthesia — most patients need crutches for one to three days and can resume light daily activity within the same week. Full hip loading and return to sport is typically reached within three to six months as the collagen scaffold integrates and remodelling progresses.

AMIC involves a more substantial immediate commitment: theatre access, general or spinal anaesthesia, and a structured post-operative period, including protected weight-bearing in the early weeks and supervised physiotherapy throughout the repair maturation phase. Return to unrestricted activity generally takes longer than six months, guided by how well the repair bed consolidates and the membrane-stabilised tissue matures.

Despite the difference in recovery arc, both pathways benefit from active rehabilitation. Appropriately phased joint loading — whether the repair is scaffold-based or surgically induced — supports tissue maturation; the injection route is less invasive but not a low-effort alternative.

Where lesion characteristics make both pathways technically eligible, the choice between a lower-burden injection and a structural surgical rebuild turns on individual circumstances, rehabilitation capacity, and imaging-confirmed joint status — factors that require specialist assessment rather than a procedure-name preference.

Lincolnshire Hip is part of the MSK Doctors group and accepts patients without referral for hip assessment, with clinics in Sleaford and Grantham available across Lincolnshire and the wider non-London UK catchment.